Sparsentan: A New Dual Endothelin Angiotensin Receptor Antagonist-Synpharyngitic Glomerulonephrities

Author(s):

Deepak Dalal* and Ravi Kant

Sparsentan is a newly approved Dual Endothelin Angiotensin Receptor Antagonist for glomerulosclerosis and IgA nephropathy. Sparsentan is dual-acting, highly selective antagonist has as its targets both the Endothelin A Receptor (ETAR) and the Angiotensin II Subtype 1 Receptor (AT1R). In the Phase 2 EPPIK study, sparsentan's potential and safety for long-term Nephroprotection and Antiproteinuria in children with focal segmental glomerulosclerosis, Minimal Change Disease (MCD), IgA nephropathy, IgAV, and Alport Syndrome (AS) will be examined. IgA nephropathy, also known as Berger's disease (variations) and synpharyngitic glomerulonephritis, is an immune system and kidney disease. It is a particular kind of glomerulonephritis, which is an inflammation of the glomeruli in the kidney. Sparsentan is certified by the US FDA In January 2023. In this article, the major events that resulted in saparsentan initial approval for the treatment of people with primary immunoglobulin A nephropathy, proteinuria is present are discussed.